<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} Open Forum Infect DisOpen Forum Infect DisofidOpen Forum" exact="Infectious" post="Diseases2328-8957Oxford University PressUS pmcid: 7033915 doi: 10.1093/ofid/ofaa040ofaa040 : Major"/>
 <result pre="SchoolGermany[3], University of Liverpool, Clinical PharmacologyUnited Kingdom[4], German Center for" exact="Infection" post="Research (Deutsches Zentrum für Infektionsforschung DZIF)Germany Correspondence: Benjamin Maasoumy,"/>
 <result pre="Abstract Background With the introduction of direct-acting antivirals (DAAs) for" exact="hepatitis" post="C virus (HCV) infection, drug–drug interactions (DDIs) emerged as"/>
 <result pre="and the infected population have rapidly changed. So far, very" exact="limited" post="data are available regarding the clinical relevance of DDIs"/>
 <result pre="38.8%). The recently approved DAAs (period C) theoretically showed a" exact="lower" post="DDI risk profile. However, real-world DDIs were still comparable"/>
 <result pre="antiviral treatment still affect about 40% of HCV patients. The" exact="lower" post="DDI potential of modern DAA regimens is partly counteracted"/>
 <result pre="should not be underestimated. direct-acting antivirals (DAAs) drug–drug interactions (DDIs)" exact="hepatitis" post="C virus (HCV) infection patient characteristics polypharmacy Funding German"/>
 <result pre="direct-acting antivirals (DAAs) drug–drug interactions (DDIs) hepatitis C virus (HCV)" exact="infection" post="patient characteristics polypharmacy Funding German Center for Infection Research10.13039/100009139"/>
 <result pre="virus (HCV) infection patient characteristics polypharmacy Funding German Center for" exact="Infection" post="Research10.13039/100009139 page-count: In 2015, ~71 million people worldwide suffered"/>
 <result pre="Research10.13039/100009139 page-count: In 2015, ~71 million people worldwide suffered from" exact="chronic hepatitis" post="C virus (HCV) infection [1]. Currently the World Health"/>
 <result pre="page-count: In 2015, ~71 million people worldwide suffered from chronic" exact="hepatitis" post="C virus (HCV) infection [1]. Currently the World Health"/>
 <result pre="million people worldwide suffered from chronic hepatitis C virus (HCV)" exact="infection" post="[1]. Currently the World Health Organization (WHO) is calling"/>
 <result pre="Health Organization (WHO) is calling for a reduction of new" exact="infections" post="by 90% and mortality by 65% by 2030, with"/>
 <result pre="limitations. Both PIs were accompanied by considerable adverse events like" exact="anemia" post="or skin rash; their usage was mainly restricted to"/>
 <result pre="restricted to HCV genotype 1, and their efficacy was rather" exact="limited" post="[2–5]. Combination with pegylated interferon α (PEG-IFN α) was"/>
 <result pre="not eligible for therapy, and many of those with mild" exact="disease" post="chose to defer treatment [7–9]. Furthermore, drug–drug interactions (DDIs)"/>
 <result pre="DDI via, for example, CYP 3A4 or P-gp is significantly" exact="lower" post="as compared with previously used regimens. However, it has"/>
 <result pre="remaining HCV population. METHODS Cohort Overall, 668 consecutive patients with" exact="chronic" post="HCV infection who were treated with a DAA regimen"/>
 <result pre="population. METHODS Cohort Overall, 668 consecutive patients with chronic HCV" exact="infection" post="who were treated with a DAA regimen at the"/>
 <result pre="infection who were treated with a DAA regimen at the" exact="hepatitis" post="outpatient clinic of Hannover Medical School from January 2014"/>
 <result pre="the INNO-LiPA by Innogenetics according to the manufacturer’s instructions. Liver" exact="cirrhosis" post="in patients was calculated using transient elastography. The applied"/>
 <result pre="the manufacturer’s instructions. Liver cirrhosis in patients was calculated using" exact="transient" post="elastography. The applied cutoff value for cirrhosis was &amp;gt;13 kPa"/>
 <result pre="was calculated using transient elastography. The applied cutoff value for" exact="cirrhosis" post="was &amp;gt;13 kPa [32]. In case of failed transient elastography,"/>
 <result pre="value for cirrhosis was &amp;gt;13 kPa [32]. In case of failed" exact="transient" post="elastography, additional clinical and laboratory parameters (ie, albumin, bilirubin,"/>
 <result pre="and stage of encephalopathy) were used to determine the stage" exact="of liver" post="cirrhosis. Before treatment, all patients included in this retrospective"/>
 <result pre="stage of encephalopathy) were used to determine the stage of" exact="liver cirrhosis." post="Before treatment, all patients included in this retrospective analysis"/>
 <result pre="were assessed between all regular outpatient medications used in the" exact="total" post="cohort and each individual antiviral that was available for"/>
 <result pre="individual antiviral that was available for the treatment of HCV" exact="infection" post="in the last decade. Administration of a fixed-dose combination"/>
 <result pre="included in the analysis; 45.1% were female, and 45.1% had" exact="liver cirrhosis." post="The median number of drugs in the regular outpatient"/>
 <result pre="mean age of the patients fluctuated over time, with a" exact="lower" post="mean age of the patients in the most recent"/>
 <result pre="B–C P = .079, and A–C P = .235). Of note, the frequency of" exact="cirrhosis" post="among the patients receiving antiviral treatment declined significantly over"/>
 <result pre="were ≥65 years old and ≥75 years old, respectively. The frequency of" exact="cirrhosis" post="was 52.0%. Table 1. Baseline Characteristics of the Cohort"/>
 <result pre="cirrhosis was 52.0%. Table 1. Baseline Characteristics of the Cohort" exact="Total" post="Cohort Jan 2014–Nov 2014 Nov 2014–Aug 2016 Aug 2016–Jul"/>
 <result pre="(100.0) 162 (24.3) 256 (38.3) 250 (37.4) Sex, No. (%)" exact="Female" post="301 (45.1) 65 (40.1) 122 (47.7) 114 (45.6) Male"/>
 <result pre="median (range) 3 (0–19) 3 (0–18) 3 (0–16) 2 (0–19)" exact="Kidney" post="transplant patients receiving sirolimus, everolimus, cyclosporine, or tacrolimus 16"/>
 <result pre="16 (2.4) 0 (0) 6 (2.3) 10 (4.0) Abbreviations: HCV," exact="hepatitis" post="C virus; N/A, not available. Figure 1. A, Number"/>
 <result pre="weak DDI (category 2). Overall, the potential for DDIs was" exact="lower" post="compared with most of the older IFN-free regimens (Figure"/>
 <result pre="Figure 3. Real occurring drug–drug interactions between outpatient medications and" exact="hepatitis" post="C virus (HCV) regimens for each patient at baseline."/>
 <result pre="for each patient at baseline depending on the presence of" exact="cirrhosis" post="and age. E, Real occurring drug–drug interactions between outpatient"/>
 <result pre="orange: potential significant interaction; red: do not coadminister. Patients with" exact="cirrhosis" post="and those aged ≥65 years used significantly more concomitant medications"/>
 <result pre="used significantly more concomitant medications (mean number of drugs, no" exact="cirrhosis" post="vs cirrhosis: 3.2 vs 4.3, P &amp;lt; .001; &amp;lt;65 years vs"/>
 <result pre="1.14–1.63; age ≥65 years: RR, 1.79; 95% CI, 1.52–2.11). Among patients with" exact="cirrhosis" post="(n = 301), 42.5% had potential significant DDIs (category 3) with"/>
 <result pre="respective DAA therapy, in comparison with 28.9% of patients without" exact="cirrhosis" post="(P &amp;lt; .001). The frequency of contraindicated outpatient medication was similar"/>
 <result pre="ELB/GRZ (n = 73) interactions were mediated via CYP enzymes (49.0%) and" exact="breast cancer" post="resistance protein (BCRP; 27.5%) most of the time. This"/>
 <result pre="(n = 73) interactions were mediated via CYP enzymes (49.0%) and breast" exact="cancer" post="resistance protein (BCRP; 27.5%) most of the time. This"/>
 <result pre="statin blood levels, and the risk for adverse events like" exact="rhabdomyolysis" post="increases. In contrast to that, VEL/SOF ± VOX (without VOX: n = 58;"/>
 <result pre="were due to a PPI increasing gastric pH, thereby causing" exact="lower" post="absorption rates of mainly VEL. DDIs between regular outpatient"/>
 <result pre="interaction mechanisms between outpatient medications and HCV regimens. Abbreviations: BCRP," exact="breast cancer" post="resistance protein; CYP, cytochrome P450 enzyme; IMDH, inosine-5’-monophosphate dehydrogenase;"/>
 <result pre="mechanisms between outpatient medications and HCV regimens. Abbreviations: BCRP, breast" exact="cancer" post="resistance protein; CYP, cytochrome P450 enzyme; IMDH, inosine-5’-monophosphate dehydrogenase;"/>
 <result pre="with the approval of DAAs for the treatment of HCV" exact="infection" post="[11]. Although this work for the first time provides"/>
 <result pre="DAAs demonstrate a moderate DDI risk profile, which is significantly" exact="lower" post="compared with first-generation PIs used from 2011 or the"/>
 <result pre="of DDIs in the real-world analysis remained more or less" exact="stable" post="over the treatment periods, with about 40% of HCV"/>
 <result pre="(ie, higher frequency of polypharmacy) at least partly counteracted the" exact="lower" post="potential risk for DDI with the newer DAA regimens."/>
 <result pre="the different treatment periods. The frequency of treated patients with" exact="cirrhosis" post="has significantly decreased. In addition, the mean age of"/>
 <result pre="treatment policy over the last years. Patients with advanced stages" exact="of liver" post="disease were treated first at our and several other"/>
 <result pre="policy over the last years. Patients with advanced stages of" exact="liver disease" post="were treated first at our and several other centers"/>
 <result pre="over the last years. Patients with advanced stages of liver" exact="disease" post="were treated first at our and several other centers"/>
 <result pre="center. Thus, a higher frequency of patients with more advanced" exact="liver disease" post="is likely, as indicated by the higher-than-average rate of"/>
 <result pre="Thus, a higher frequency of patients with more advanced liver" exact="disease" post="is likely, as indicated by the higher-than-average rate of"/>
 <result pre="it should be noted that it was not patients with" exact="cirrhosis" post="but rather elderly patients who showed a comparably higher"/>
 <result pre="ever. Supplementary Data Supplementary materials are available at Open Forum" exact="Infectious" post="Diseases online. Consisting of data provided by the authors"/>
 <result pre="Supplementary Data Supplementary materials are available at Open Forum Infectious" exact="Diseases" post="online. Consisting of data provided by the authors to"/>
 <result pre="work was partly funded by the DZIF (German Center for" exact="Infection" post="Research). Potential conflicts of interest. F.M. received financial support"/>
 <result pre="supervised the work. References References 1.collab: World Health Organization. Global" exact="hepatitis" post="report2017 Available at: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=6120C81F258231FE3F7294BE3E90786C?sequence=1. Accessed 2 March 2019. 2.McHutchisonJG,"/>
 <result pre="et al.collab: PROVE1 Study TeamTelaprevir with peginterferon and ribavirin for" exact="chronic" post="HCV genotype 1 infection. N Engl J Med2009; 360:1827–38.19403902"/>
 <result pre="with peginterferon and ribavirin reduces HCV RNA in patients with" exact="chronic" post="genotype 2 but not genotype 3 infections. Gastroenterology2011; 141:881–889.e1.21699786"/>
 <result pre="141:881–889.e1.21699786 4.PoordadF, McConeJJr, BaconBR, et al.collab: SPRINT-2 InvestigatorsBoceprevir for untreated" exact="chronic" post="HCV genotype 1 infection. N Engl J Med2011; 364:1195–206.21449783"/>
 <result pre="GordonSC, LawitzE, et al.collab: HCV RESPOND-2 InvestigatorsBoceprevir for previously treated" exact="chronic" post="HCV genotype 1 infection. N Engl J Med2011; 364:1207–17.21449784"/>
 <result pre="PROVE2 Study TeamTelaprevir and peginterferon with or without ribavirin for" exact="chronic" post="HCV infection. N Engl J Med2009; 360:1839–50.19403903 7.MaasoumyB, PortK,"/>
 <result pre="PortK, MarkovaAA, et al.Eligibility and safety of triple therapy for" exact="hepatitis" post="C: lessons learned from the first experience in a"/>
 <result pre="effectiveness and safety profile of protease inhibitor-based triple therapy against" exact="chronic hepatitis" post="C in a real-world cohort with a high proportion"/>
 <result pre="and safety profile of protease inhibitor-based triple therapy against chronic" exact="hepatitis" post="C in a real-world cohort with a high proportion"/>
 <result pre="in a real-world cohort with a high proportion of advanced" exact="liver disease." post="Eur J Gastroenterol Hepatol2014; 26:836–45.24987822 10.MaasoumyB, PortK, Calle SerranoB,"/>
 <result pre="drug-drug interactions in the era of direct-acting anti-viral agents against" exact="chronic hepatitis" post="C. Aliment Pharmacol Ther2013; 38:1365–72.24127648 11.KiserJJ, BurtonJRJr, EversonGTDrug-drug interactions"/>
 <result pre="interactions in the era of direct-acting anti-viral agents against chronic" exact="hepatitis" post="C. Aliment Pharmacol Ther2013; 38:1365–72.24127648 11.KiserJJ, BurtonJRJr, EversonGTDrug-drug interactions"/>
 <result pre="Ther2013; 38:1365–72.24127648 11.KiserJJ, BurtonJRJr, EversonGTDrug-drug interactions during antiviral therapy for" exact="chronic hepatitis" post="C. Nat Rev Gastroenterol Hepatol2013; 10:596–606.23817323 12.DechanontS, MaphantaS, ButthumB,"/>
 <result pre="38:1365–72.24127648 11.KiserJJ, BurtonJRJr, EversonGTDrug-drug interactions during antiviral therapy for chronic" exact="hepatitis" post="C. Nat Rev Gastroenterol Hepatol2013; 10:596–606.23817323 12.DechanontS, MaphantaS, ButthumB,"/>
 <result pre="after adding simeprevir- or sofosbuvir-containing therapy to medication profiles of" exact="hepatitis" post="C monoinfected patients. Infect Dis Ther2015; 4:67–78. 14.Höner Zu"/>
 <result pre="et al.Eligibility and safety of the first interferon-free therapy against" exact="hepatitis" post="C in a real-world setting. Liver Int2015; 35:1845–1852.25556625 15.AfdhalN,"/>
 <result pre="ION-3 InvestigatorsLedipasvir and sofosbuvir for 8 or 12 weeks for" exact="chronic" post="HCV without cirrhosis. N Engl J Med2014; 370:1879–88.24720702 18.FeldJJ,"/>
 <result pre="19.PoordadF, HezodeC, TrinhR, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for" exact="hepatitis" post="C with cirrhosis. N Engl J Med2014; 370:1973–82.24725237 20.Höner"/>
 <result pre="and clinical significance of drug-drug interactions in elderly patients with" exact="chronic hepatitis" post="C virus infection. Aliment Pharmacol Ther2016; 44:856–65.27549000 22.MarraF, Höner"/>
 <result pre="clinical significance of drug-drug interactions in elderly patients with chronic" exact="hepatitis" post="C virus infection. Aliment Pharmacol Ther2016; 44:856–65.27549000 22.MarraF, Höner"/>
 <result pre="of drug-drug interactions in elderly patients with chronic hepatitis C" exact="virus infection." post="Aliment Pharmacol Ther2016; 44:856–65.27549000 22.MarraF, Höner Zu SiederdissenC, KhooS,"/>
 <result pre="et al.Real-life data on potential drug-drug interactions in patients with" exact="chronic hepatitis" post="C viral infection undergoing antiviral therapy with interferon-free DAAs"/>
 <result pre="al.Real-life data on potential drug-drug interactions in patients with chronic" exact="hepatitis" post="C viral infection undergoing antiviral therapy with interferon-free DAAs"/>
 <result pre="on potential drug-drug interactions in patients with chronic hepatitis C" exact="viral infection" post="undergoing antiviral therapy with interferon-free DAAs in the PITER"/>
 <result pre="potential drug-drug interactions in patients with chronic hepatitis C viral" exact="infection" post="undergoing antiviral therapy with interferon-free DAAs in the PITER"/>
 <result pre="et al.Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with" exact="hepatitis" post="C virus genotype 1 infection and stage 4-5 chronic"/>
 <result pre="treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1" exact="infection" post="and stage 4-5 chronic kidney disease (the C-SURFER study):"/>
 <result pre="with hepatitis C virus genotype 1 infection and stage 4-5" exact="chronic" post="kidney disease (the C-SURFER study): a combination phase 3"/>
 <result pre="hepatitis C virus genotype 1 infection and stage 4-5 chronic" exact="kidney disease" post="(the C-SURFER study): a combination phase 3 study. Lancet2015;"/>
 <result pre="C virus genotype 1 infection and stage 4-5 chronic kidney" exact="disease" post="(the C-SURFER study): a combination phase 3 study. Lancet2015;"/>
 <result pre="KwoPY, et al.Safety and efficacy of elbasvir/grazoprevir in patients with" exact="hepatitis" post="C virus infection and compensated cirrhosis: an integrated analysis."/>
 <result pre="al.Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C" exact="virus infection" post="and compensated cirrhosis: an integrated analysis. Gastroenterology2017; 152:1372–1382.e2.28193518 28.FosterGR,"/>
 <result pre="and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus" exact="infection" post="and compensated cirrhosis: an integrated analysis. Gastroenterology2017; 152:1372–1382.e2.28193518 28.FosterGR,"/>
 <result pre="Study of the Liver (EASL). EASL recommendations on treatment of" exact="hepatitis" post="C 2018. J Hepatol2018; 69:461–511.29650333 32.Friedrich-RustM, OngMF, MartensS, et"/>
 <result pre="2018. J Hepatol2018; 69:461–511.29650333 32.Friedrich-RustM, OngMF, MartensS, et al.Performance of" exact="transient" post="elastography for the staging of liver fibrosis: a meta-analysis."/>
 <result pre="OngMF, MartensS, et al.Performance of transient elastography for the staging" exact="of liver" post="fibrosis: a meta-analysis. Gastroenterology2008; 134:960–74.18395077 33.WedemeyerH, DoreGJ, WardJWEstimates on"/>
 <result pre="fibrosis: a meta-analysis. Gastroenterology2008; 134:960–74.18395077 33.WedemeyerH, DoreGJ, WardJWEstimates on HCV" exact="disease" post="burden worldwide - filling the gaps. J Viral Hepat2015;"/>
 <result pre="on HCV disease burden worldwide - filling the gaps. J" exact="Viral" post="Hepat2015; 22(Suppl 1):1–5. 34.KittnerJM, WeissNM, WiltinkJ, et al.Defer or"/>
 <result pre="al.Defer or treat? Reasons for treatment decisions in patients with" exact="chronic hepatitis" post="C genotype 1 in the early era of directly"/>
 <result pre="or treat? Reasons for treatment decisions in patients with chronic" exact="hepatitis" post="C genotype 1 in the early era of directly"/>
 <result pre="SOLAR-1 InvestigatorsLedipasvir and sofosbuvir plus ribavirin for treatment of HCV" exact="infection" post="in patients with advanced liver disease. Gastroenterology2015; 149:649–59.25985734 36.MannsM,"/>
 <result pre="ribavirin for treatment of HCV infection in patients with advanced" exact="liver disease." post="Gastroenterology2015; 149:649–59.25985734 36.MannsM, SamuelD, GaneEJ, et al.collab: SOLAR-2 InvestigatorsLedipasvir"/>
 <result pre="sofosbuvir plus ribavirin in patients with genotype 1 or 4" exact="hepatitis" post="C virus infection and advanced liver disease: a multicentre,"/>
 <result pre="ribavirin in patients with genotype 1 or 4 hepatitis C" exact="virus infection" post="and advanced liver disease: a multicentre, open-label, randomised, phase"/>
 <result pre="in patients with genotype 1 or 4 hepatitis C virus" exact="infection" post="and advanced liver disease: a multicentre, open-label, randomised, phase"/>
 <result pre="et al.Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with" exact="hepatitis" post="C virus infection. Hepatology2018; 68:1298–307.29672891 38.GonzalezSA, TrotterJFThe rise of"/>
 <result pre="treatment in liver or kidney transplant patients with hepatitis C" exact="virus infection." post="Hepatology2018; 68:1298–307.29672891 38.GonzalezSA, TrotterJFThe rise of the opioid epidemic"/>
 <result pre="Hepatology2018; 68:1298–307.29672891 38.GonzalezSA, TrotterJFThe rise of the opioid epidemic and" exact="hepatitis" post="C-positive organs: a new era in liver transplantation. Hepatology2018;"/>
 <result pre="TrivediHD, NaderCPharmacokinetics and drug interactions of medications used to treat" exact="hepatitis" post="C virus infection in the setting of chronic kidney"/>
 <result pre="and drug interactions of medications used to treat hepatitis C" exact="virus infection" post="in the setting of chronic kidney disease and kidney"/>
 <result pre="drug interactions of medications used to treat hepatitis C virus" exact="infection" post="in the setting of chronic kidney disease and kidney"/>
 <result pre="to treat hepatitis C virus infection in the setting of" exact="chronic" post="kidney disease and kidney transplantation. Hemodial Int2018; 22(Suppl 1):22–35."/>
 <result pre="treat hepatitis C virus infection in the setting of chronic" exact="kidney disease" post="and kidney transplantation. Hemodial Int2018; 22(Suppl 1):22–35. 40.YuG, ZhengY,"/>
 <result pre="hepatitis C virus infection in the setting of chronic kidney" exact="disease" post="and kidney transplantation. Hemodial Int2018; 22(Suppl 1):22–35. 40.YuG, ZhengY,"/>
 <result pre="YuY, et al.Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for" exact="hepatitis" post="C virus infection: clinical relevance and mitigation strategies. Drug"/>
</results>
